MERIT Study – Ozurdex (dexamethasone implant, Abbvie) does not resolve the edema in almost half of MESI patients at any point, and the treatment effect wanes by Week 12 51 Acharya NR, et al. Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results. Ophthalmology. 2023 Sep;130(9):914-923. Even at the maximum drying effect of Ozurdex, which is observed at Week 8, the visual acuity gains are modest, and also wane by Week 12 -5 0 5 10 15 0 4 8 12 Dexamethasone implant Dexamethasone implant Letters Proportion of eyes with normalization of OCT CST Mean change in BCVA Patients, %